HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

SIMPLE SUMMARY: Classical clinical research has been developed according to immunohistochemical breast cancer subtypes, instead of designing trials specifically for each molecular subtype. Efforts in de-escalating treatment should focus on identifying a subgroup of HER2 oncogene addicted tumours tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Bueno Muiño, Coralia, Martín, Miguel, del Monte-Millán, María, García-Saénz, José Ángel, López-Tarruella, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833556/
https://www.ncbi.nlm.nih.gov/pubmed/35158778
http://dx.doi.org/10.3390/cancers14030512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833556/
https://www.ncbi.nlm.nih.gov/pubmed/35158778
http://dx.doi.org/10.3390/cancers14030512

Ejemplares similares